InMed Shares Pre-Clinical Data from Co-Sponsored Study

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) announced the results from a co-sponsored study with the University of British Columbia.
As quoted in the press release:

The InMed-UBC study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye, resulting in enhanced drug uptake via the cornea and lens.
“Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward”, said Eric A. Adams, President & CEO of InMed.  “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.”
Further disclosure of study data is embargoed pending publication in a peer-reviewed journal.

Click here to read the full press release.

Source: www.newswire.ca